ProQR Therapeutics (PRQR) News Today $1.33 -0.04 (-2.92%) Closing price 04:00 PM EasternExtended Trading$1.32 -0.01 (-0.38%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest ProQR Therapeutics Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Financial Comparison: ProQR Therapeutics (NASDAQ:PRQR) & aTyr Pharma (NASDAQ:ATYR)October 20 at 4:29 AM | americanbankingnews.comProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Has Average Target Price of $7.60October 18, 2026 | americanbankingnews.comProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Has Consensus Price Target of $7.60 According to AnalystsOctober 18, 2026 | marketbeat.comFY2028 Earnings Estimate for PRQR Issued By HC WainwrightOctober 5, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Sagimet Biosciences, Inc. Class A (SGMT)October 2, 2026 | theglobeandmail.comProQR Reports First Human Validation of RNA Editing Platform in Liver DiseaseOctober 2, 2026 | marketbeat.comProQR Therapeutics' (PRQR) "Buy" Rating Reiterated at Chardan CapitalOctober 1, 2026 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Stock Price Target Lowered at HC WainwrightOctober 1, 2026 | marketbeat.comProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI AdvisorSeptember 23, 2026 | globenewswire.comProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Moderate Buy" from BrokeragesSeptember 23, 2026 | marketbeat.comProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease TreatmentSeptember 10, 2026 | finance.yahoo.comProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026September 9, 2026 | globenewswire.comProQR to Participate in Upcoming Investor Conferences in September 2026September 2, 2026 | globenewswire.comProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other CatalystsAugust 21, 2026 | seekingalpha.comProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 ResultsAugust 15, 2026 | theglobeandmail.comProQR posts Q2 2026 results as Axiomer RNA editing gains first clinical validationAugust 15, 2026 | theglobeandmail.comProQR Therapeutics Reports First Clinical Validation of Axiomer RNA Editing Platform, Positive AX-0810 Data and Upcoming Pipeline MilestonesAugust 13, 2026 | quiverquant.comQProQR Announces Second Quarter 2026 Operating and Financial ResultsAugust 13, 2026 | globenewswire.comBart Filius Purchases 150,000 Shares of ProQR Therapeutics (NASDAQ:PRQR) StockJuly 29, 2026 | insidertrades.comOppenheimer Reaffirms Their Buy Rating on ProQR (PRQR)July 11, 2026 | theglobeandmail.comProQR Therapeutics: Human NTCP Data Strengthens The Axiomer ThesisJuly 4, 2026 | seekingalpha.comProQR Therapeutics (NASDAQ:PRQR) Director Purchases 150,000 Shares of StockJuly 1, 2026 | insidertrades.comProQR prices $50M stock offering; secures $9.2M investment from Eli LillyJune 25, 2026 | msn.comProQR posts early-stage trial data for liver disease candidateJune 25, 2026 | msn.comProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private PlacementJune 25, 2026 | globenewswire.comProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing PlatformJune 25, 2026 | globenewswire.comPRQR Share News TodayJune 11, 2026 | uk.investing.comProQR Shareholders Approve Capital Increase, Board Changes at 2026 AGMJune 2, 2026 | tipranks.comProQR Posts Wider Q1 2026 Loss but Maintains Strong Cash PositionMay 17, 2026 | theglobeandmail.comProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%May 14, 2026 | finance.yahoo.comProQR Announces First Quarter 2026 Operating and Financial ResultsMay 12, 2026 | globenewswire.comProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing PlatformMay 11, 2026 | globenewswire.comProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026May 4, 2026 | globenewswire.comProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of DirectorsApril 30, 2026 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS), ProQR (PRQR) and Simulations Plus (SLP)April 10, 2026 | theglobeandmail.comProQR Therapeutics: Waiting On Proof As AX-0810 Data ApproachesApril 10, 2026 | seekingalpha.comProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst EventApril 8, 2026 | globenewswire.comProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory BoardApril 8, 2026 | globenewswire.comGrowing optimism about ProQR Therapeutics (PRQR)’s RNA editing platform and future clinical catalystsMarch 26, 2026 | msn.comProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026March 25, 2026 | globenewswire.comProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 TranscriptMarch 18, 2026 | seekingalpha.comProQR Therapeutics N.V.: ProQR Announces Year End 2025 Operating and Financial ResultsMarch 12, 2026 | finanznachrichten.deProQR Announces Year End 2025 Operating and Financial ResultsMarch 12, 2026 | globenewswire.comProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences ConferenceMarch 3, 2026 | globenewswire.comProQR Announces Planned Changes to Board CompositionFebruary 9, 2026 | globenewswire.comProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 OutlookJanuary 8, 2026 | globenewswire.comProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are individual investors with 34% stake, while 29% is held by institutionsDecember 28, 2025 | finance.yahoo.comProQR Therapeutics N.V. to Participate in 8th Annual Evercore Healthcare Conference on December 4, 2025December 1, 2025 | quiverquant.comQProQR to Participate in 8th Annual Evercore Healthcare ConferenceDecember 1, 2025 | globenewswire.comProQR Therapeutics reports Q3 (EUR 0.10) vs (EUR 0.10) last yearNovember 7, 2025 | msn.com ProQR Therapeutics Media Mentions By Week ProQR Therapeutics Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRQR News Sentiment▼-0.030.47▲Average Healthcare News Sentiment ProQR Therapeutics News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRQR Articles This Week▼32▲PRQR Articles Average Week ProQR Therapeutics Trends on MarketBeatThis week vs. last weekNew Followers1-50%Searches1Page Views1,782-26% Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Pharming Group News Today Aura Biosciences News Today Immix Biopharma News Today Prime Medicine News Today WAVE Life Sciences News Today Sinovac Biotech News Today Olema Pharmaceuticals News Today Nuvectis Pharma News Today Climb Bio News Today Ironwood Pharmaceuticals News Today News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for ProQR Therapeutics dated 10/18/2026. From Our PartnersElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
